

# Table of Contents

## PART I. SHERMAN ACT

### CHAPTER 1. PRICE-FIXING AGREEMENTS

- § 1:1 Overview
- § 1:2 Direct evidence of price-fixing
- § 1:3 Per se rule or rule of reason?
- § 1:4 Agreements indirectly involving price
- § 1:5 Bid rigging
- § 1:6 Surreptitiously-obtained evidence of price fixing
- § 1:7 Class actions involving price fixing claims
- § 1:8 Sufficiency of civil complaint based on criminal case
- § 1:9 The single enterprise theory—*Copperweld* and *American Needle*
- § 1:10 State antitrust laws
- § 1:11 Exemptions and immunities
- Appendix 1-A. Sherman Act Violations Yielding a Corporate Fine of \$10 Million or More as of 02/16/2017
- Appendix 1-B. KYB Sentencing Memo

### CHAPTER 2. PROOF OF PRICE-FIXING BY CIRCUMSTANTIAL EVIDENCE

- § 2:1 Introduction
- § 2:2 Proof by circumstantial evidence
- § 2:3 —Suspicious bidding practices
- § 2:4 —Possession of competitor's price list
- § 2:5 —Behavior in other markets
- § 2:6 —Evidence of solicitation of price-fixing
- § 2:7 —Combination of factors
- § 2:8 Conscious parallelism
- § 2:9 —The concept of interdependence
- § 2:10 —Plus factors
- § 2:11 — —Conspiratorial motivation
- § 2:12 — —Opportunity to conspire
- § 2:13 — —Prior conspiracy
- § 2:14 — —Actions against self-interest
- § 2:15 —Pattern of uniform acts
- § 2:16 —Plus factors—Multiple factors
- § 2:17 Price announcements
- § 2:18 Sufficiency of complaints post-*Twombly*

§ 2:19 Direct versus circumstantial evidence

## CHAPTER 3. VERTICAL ARRANGEMENTS

- § 3:1 Introduction
- § 3:2 Rationales for and against vertical restraints
- § 3:3 Customer and territorial restrictions
- § 3:4 The evolving view of resale price maintenance
- § 3:5 The precedent-setting decision in *Leegin*
- § 3:6 Negative Reaction to *Leegin* and continued uncertainty about RPM
- § 3:7 Post-*Leegin* decisions
- § 3:8 Specific distribution practices
- § 3:9 —National account programs
- § 3:10 —The line between RPM and MAP
- § 3:11 Exclusive dealing arrangements
- § 3:12 Standing to file private cause of action—Distributors
- § 3:13 —Consumers
- § 3:14 Conclusion

## CHAPTER 4. MONOPOLIZATION

- § 4:1 Introduction
- § 4:2 Monopolization
- § 4:3 —Pharmaceutical litigation—*Actavis* and other cases
- § 4:4 —Maintenance of monopoly power—*Section 5 of the FTC Act*
- § 4:5 Monopoly power
- § 4:6 Relevant market
- § 4:7 —Relevant product market
- § 4:8 —Relevant geographic market
- § 4:9 Anticompetitive conduct—Willful acquisition or maintenance
- § 4:10 —Predatory pricing
- § 4:11 —Refusal to deal
- § 4:12 —Vertical integration
- § 4:13 —Product introduction/innovation
- § 4:14 —Leveraging
- § 4:15 —Other activities
- § 4:16 Bundling and Loyalty Programs
- § 4:17 Intellectual property and monopolization—Patents and Monopolization
- § 4:18 —Copyrights and Monopolization
- § 4:19 Attempt to monopolize
- § 4:20 —Specific intent
- § 4:21 —Anticompetitive conduct
- § 4:22 —Dangerous probability of success
- § 4:23 —Attempted joint monopolization

## TABLE OF CONTENTS

- § 4:24 Combination or conspiracy to monopolize
- § 4:25 Remedies for section 2 violations
- § 4:26 Conclusion

## CHAPTER 5. INFORMATION EXCHANGES

- § 5:1 Introduction
- § 5:2 Exchange of pricing information—Purpose of the exchange
- § 5:3 Price information—Anticompetitive effect becomes the standard
- § 5:4 —“Controlling circumstances” exception limited
- § 5:5 —Legitimate business reasons for the exchange
- § 5:6 —Other theories used to prosecute price information exchanges
- § 5:7 Statistical information—Intellectual property information
- § 5:8 —Confidential business information
- § 5:9 Salary information exchanges
- § 5:10 Credit information exchange
- § 5:11 Exchanges of information between competitors—Price “signaling” and “price scraping”
- § 5:12 Administrative guidance
- § 5:13 —Business review letters
- § 5:14 — —Challenged transactions
- § 5:15 — —Unchallenged transactions
- § 5:16 —Consent decrees
- § 5:17 —Health care guidelines
- § 5:18 — —Hospital information exchanges antitrust safety zone
- § 5:19 — —Hospital information exchanges outside the antitrust safety zone
- § 5:20 — —ACOs
- § 5:21 — —Business review examples
- § 5:22 —Competitor collaborations guidelines
- § 5:23 —Practical advice

## CHAPTER 6. TYING

- § 6:1 Introduction
- § 6:2 Statutory prohibitions—Sherman, Clayton, and FTC Acts
- § 6:3 The standard of analysis—*Per Se v. Rule of Reason*
- § 6:4 Elements of a tying claim
- § 6:5 —Two separate products
- § 6:6 — —Distribution and full-line forcing
- § 6:7 —Conditioning and Coercion
- § 6:8 —Is “bundling” a tying arrangement?
- § 6:9 —Market power

- § 6:10 —No presumption of market power from patent
- § 6:11 —A “not insubstantial” (vs. a “substantial”) effect in the tied product market
- § 6:12 —Economic interest
- § 6:13 Antitrust Injury in Tying Cases
- § 6:14 Defenses
- § 6:15 Tying and the DOJ-FTC IP antitrust guidelines
- § 6:16 Procedural issues in tying Litigation—Class actions—Classwide proof of injury
- § 6:17 Conclusion

## CHAPTER 7. HORIZONTAL BOYCOTTS

- § 7:1 Introduction
- § 7:2 Supreme Court cases on group boycott
- § 7:3 Rule of reason versus per se analysis
- § 7:4 Boycotts involving the health care industry—Denial of staff privileges and similar arrangements
- § 7:5 —Enforcement of ethical rules
- § 7:6 —Efforts by providers to resist health care cost controls
- § 7:7 Noneconomic boycotts
- § 7:8 Joint ventures
- § 7:9 Proof of concerted action
- § 7:10 Capability to conspire—Post-*Copperweld*, post-*American Needle*
- § 7:11 Sufficiency of complaints, post-*Twombly*
- § 7:12 Conclusion

## PART II. CLAYTON ACT

### CHAPTER 8. MERGER ANALYSIS

- § 8:1 Introduction
- § 8:2 Frequency of DOJ and FTC merger challenges
- § 8:3 Congressional Efforts to Revise the FTC’s Merger Authority
- § 8:4 Overview of merger law
- § 8:5 DOJ/FTC Horizontal Merger Guidelines
- § 8:6 Analysis of horizontal mergers—Defining the relevant product market
- § 8:7 — —The *DuPont* test
- § 8:8 — —The *Brown Shoe* test
- § 8:9 — —The *Kodak* analysis
- § 8:10 —The relevant “product” market in high-technology cases
- § 8:11 —Defining the relevant geographic market

## TABLE OF CONTENTS

§ 8:12	—The quantitative point at which a horizontal merger should be illegal
§ 8:13	—Potential adverse effects of horizontal mergers
§ 8:14	— —Unilateral effects
§ 8:15	— —Coordinated interaction
§ 8:16	—Other factors in horizontal merger analysis
§ 8:17	— —Foreign competition, ease of entry, and efficiencies
§ 8:18	—The failing-firm defense
§ 8:19	Recent healthcare merger cases
§ 8:20	Other recent horizontal merger cases
§ 8:21	Analysis of vertical mergers
§ 8:22	—Potential competition
§ 8:23	Analysis of Vertical Mergers—Unilateral Effects
§ 8:24	Analysis of vertical mergers—The elimination of a disruptive influence
§ 8:25	—Evasion of rate regulation theory
§ 8:26	Conglomerate Mergers
§ 8:27	Special industry rules
§ 8:28	—Health Care Guidelines
§ 8:29	—Hospital cases
§ 8:30	—Mergers in the defense industry
§ 8:31	Post-merger challenges
§ 8:32	Practical aspects of merger analysis
§ 8:33	Practical aspects of merger analysis—FTC v. DOJ Standards for Injunctive Relief
§ 8:34	Practical aspects of merger analysis—Risk analysis
§ 8:35	— —Legal risks
§ 8:36	— —Business risks
§ 8:37	—Should you write an opinion letter?
§ 8:38	—More practical observations—How to work with the guidelines in practice
§ 8:39	— —Tactical considerations
§ 8:40	— —Cutting a deal
§ 8:41	Merger remedies
§ 8:42	Checklist for merger and acquisition analysis
§ 8:43	Federal Trade Commission and Department of Justice acquisition checklist
§ 8:44	States and private litigants
§ 8:45	—Merger enforcement by state attorneys general
§ 8:46	—Merger litigation by private parties
§ 8:47	Conclusion

## CHAPTER 9. THE HART-SCOTT-RODINO PREMERGER NOTIFICATION RULES

§ 9:1	Introduction
§ 9:2	Notification—When must a merger be notified?

- § 9:3 —Exemptions
- § 9:4 —Can notification be avoided by manipulating the form of the transaction?
- § 9:5 —Formal interpretations
- § 9:6 —What information does the form require?
- § 9:7 —Notice to the acquired company
- § 9:8 —Planning documents and the attorney-client privilege
- § 9:9 —Disclosure of submitted documents
- § 9:10 Waiting period
- § 9:11 —The waiting period in bankruptcy
- § 9:12 —Second requests
- § 9:13 —Statement of reason for noncompliance
- § 9:14 —Investigation “clearance”
- § 9:15 —Request for early termination
- § 9:16 Enforcement actions
- § 9:17 —Failure to file
- § 9:18 — —Injunctive relief
- § 9:19 — —Inadvertent violations
- § 9:20 — —Constructive avoidance of filing requirements
- § 9:21 — —Erroneous application of exceptions to filing
- § 9:22 —Gun-jumping
- § 9:23 Special rules—Unincorporated entities
- § 9:24 — —Partnerships
- § 9:25 — —Limited liability companies
- § 9:26 —Joint ventures
- § 9:27 —Foreign transactions
- § 9:28 International considerations
- § 9:29 States and private litigants

## CHAPTER 10. JOINT VENTURES

- § 10:1 Introduction
- § 10:2 Why form a joint venture?
- § 10:3 —The positive points
- § 10:4 —The negative points
- § 10:5 Antitrust laws and guidelines affecting joint ventures
- § 10:6 —Statutes—Laws applying to mergers and acquisitions
- § 10:7 — —The Sherman Act
- § 10:8 — —The Clayton Act and the Robinson-Patman Act
- § 10:9 — —Other laws
- § 10:10 —Guidelines—Health care guidelines
- § 10:11 — —International operations guidelines
- § 10:12 — —Intellectual property guidelines
- § 10:13 — —Competitor collaborations guidelines
- § 10:14 Preformation review of joint ventures

## TABLE OF CONTENTS

- § 10:15 —Hart-Scott-Rodino premerger notification rules
- § 10:16 —National Cooperative Research and Production Act of 1993
- § 10:17 —FTC advisory opinion process
- § 10:18 —DOJ business review letters
- § 10:19 Substantive analysis of joint ventures
- § 10:20 —Fully integrated joint ventures
- § 10:21 —Production joint ventures—Rule of reason analysis and the NCRPA
- § 10:22 — —Sample cases
- § 10:23 — —Health care guidelines and production joint ventures
- § 10:24 —Research joint ventures
- § 10:25 —Network joint ventures
- § 10:26 —Joint selling and buying arrangements
- § 10:27 Substantive analysis of ancillary or collateral restraints
- § 10:28 Conclusion

## CHAPTER 11. INTERLOCKING DIRECTORATES

- § 11:1 Introduction
- § 11:2 The law—Statutory text
- § 11:3 —To whom does § 8 apply?—Threshold requirement
- § 11:4 — —The one-year grace period
- § 11:5 — —Directors and officers
- § 11:6 — —Agents
- § 11:7 — —Common carriers
- § 11:8 —Mootness
- § 11:9 —Applicability to the corporation
- § 11:10 Who can enforce § 8?—Suit by private parties
- § 11:11 What companies are “competitors”?
- § 11:12 Competition—*De minimis* rule
- § 11:13 —What corporate entities are involved?—Indirect interlocks
- § 11:14 — —Subsidiaries
- § 11:15 — —“Deputization”
- § 11:16 —Is potential competition covered?
- § 11:17 Implementing a compliance program—Does your company have a § 8 compliance program?
- § 11:18 —Establishing the ground rules—Who is going to do it?
- § 11:19 —Are you going to include subsidiaries?
- § 11:20 —How often should you analyze the situation?
- § 11:21 —How are you going to involve the directors themselves?
- § 11:22 —More suggestions

## PART III. ROBINSON-PATMAN ACT

### CHAPTER 12. THE WEBB-POMERENE ACT AND THE EXPORT TRADING COMPANY ACT OF 1982

- § 12:1 Introduction
- § 12:2 The Webb-Pomerene Act of 1918—Legislative history
- § 12:3 —Provisions of the act
- § 12:4 —Webb-Pomerene associations in practice
- § 12:5 —Case discussions
- § 12:6 —International reactions
- § 12:7 —Whither Webb-Pomerene?
- § 12:8 The Export Trading Company Act of 1982—  
Legislative history
- § 12:9 —Title I—General provisions
- § 12:10 —Title II—The Bank Export Services Act—General  
provisions
- § 12:11 — — —Banking institutions that can invest in an  
export trading company
- § 12:12 — — —Limitations on investments by bank holding  
companies
- § 12:13 — — —Limitations on extensions of credit
- § 12:14 — — —Limitations on the activities of a bank-  
affiliated export trading company
- § 12:15 — — —Notice requirement
- § 12:16 — — —Results of the BESA
- § 12:17 —Title III—Export trade certificates of review
- § 12:18 — — —Procedural requirements
- § 12:19 — — —Eligibility considerations
- § 12:20 — — —The four statutory standards
- § 12:21 — — —How to apply for a certificate of review
- § 12:22 — — —Things to consider
- § 12:23 — — —Challenges to an existing certificate
- § 12:24 — — —Challenges by the government
- § 12:25 — — —Challenges by private parties
- § 12:26 — — —Experience under Title III certification  
procedure
- § 12:27 —Title IV—The Foreign Trade Antitrust  
Improvements Act
- § 12:28 — — —Jurisdiction prior to the FTAIA
- § 12:29 — — —Changes under the FTAIA
- § 12:30 — — —The 2017 International Enforcement  
Guidelines
- § 12:31 U.S. export cartels in the twenty-first century
- § 12:32 Act of state doctrine
- § 12:33 The comity doctrine



TABLE OF CONTENTS

**PART IV. FEDERAL TRADE  
COMMISSION**

**CHAPTER 13. SECTION 5 OF THE  
FEDERAL TRADE COMMISSION ACT AS AN  
ANTITRUST LAW**

- § 13:1 Introduction
- § 13:2 History and statutory language
- § 13:3 Procedural considerations
- § 13:4 Substantive enforcement
- § 13:5 Traditional antitrust violations
- § 13:6 “Reverse payment” patent settlements—*Actavis* and later cases
- § 13:7 Nontraditional antitrust violations
- § 13:8 —Violations of the policy or spirit of the antitrust laws
- § 13:9 —Incipient violations of the antitrust laws
- § 13:10 The changing enforcement environment
- § 13:11 —Anticompetitive effects
- § 13:12 —Enforcement priorities
- § 13:13 —Procedures and substantive analysis
- § 13:14 Conclusion

**PART V. EXEMPTIONS**

**CHAPTER 14. NOERR-PENNINGTON AND  
STATE ACTION**

**A. THE NOERR-PENNINGTON DOCTRINE**

- § 14:1 Introduction
- § 14:2 Supreme Court cases
- § 14:3 Specific issues under the general rule
- § 14:4 —Petitioning for unlawful action
- § 14:5 —Threats of litigation
- § 14:6 —Soliciting criminal prosecution
- § 14:7 —Influencing standard-setting associations
- § 14:8 The sham exception
- § 14:9 —Lack of probable cause
- § 14:10 —Corrupt conduct
- § 14:11 —Success of the claim as a factor
- § 14:12 —Defensive litigation as a sham
- § 14:13 —Standing and the sham exception
- § 14:14 —Presumption of genuineness

- § 14:15 —The number of claims as a factor
- § 14:16 —Copyright/patent infringement cases and the sham exception
- § 14:17 The commercial exception
- § 14:18 Application of the doctrine in the international context
- § 14:19 Application beyond the Sherman Act

## **B. THE STATE ACTION DOCTRINE**

- § 14:20 State action doctrine

# **PART VI. INTELLECTUAL PROPERTY**

## **CHAPTER 15. ANTITRUST AND INTELLECTUAL PROPERTY**

- § 15:1 Introduction
- § 15:2 The relationship between antitrust law and intellectual property
- § 15:3 2017 Guidelines for the Licensing of Intellectual Property—Introduction
- § 15:4 Overview of Antitrust Concerns in IP Licensing Arrangements
- § 15:5 Markets affected by IP licensing arrangements
- § 15:6 Antitrust “safety zones”
- § 15:7 Common antitrust/intellectual property concerns
- § 15:8 —Acquisitions
- § 15:9 —Joint ventures
- § 15:10 —Patent misuse
- § 15:11 —Copyright misuse
- § 15:12 —Refusals to license
- § 15:13 —Package licenses/tying arrangements
- § 15:14 —Territorial restrictions
- § 15:15 —Field-of-use restrictions
- § 15:16 —Price restrictions
- § 15:17 —Time/quantity restrictions
- § 15:18 —Grantbacks
- § 15:19 —Pooling/cross-licensing
- § 15:20 —Exclusive dealing
- § 15:21 —Royalties
- § 15:22 —Extension of the monopoly period
- § 15:23 Enforcement of intellectual property rights
- § 15:24 —Fraud in obtaining the patent
- § 15:25 —Bad faith enforcement of intellectual property rights

## TABLE OF CONTENTS

- § 15:26 —The sham litigation exception
- § 15:27 Standard Essential Patents (SEPs)
- § 15:28 IP Governance Structure in Europe
- § 15:29 Conclusion

## PART VII. DISTRIBUTION

### CHAPTER 16. INTERNATIONAL DISTRIBUTION AND LICENSING

- § 16:1 Introduction
- § 16:2 International antitrust concerns
- § 16:3 International licensing of intellectual property
- § 16:4 Export controls
- § 16:5 Anticorruption laws
- § 16:6 Antiboycott laws
- § 16:7 International dispute resolution
- § 16:8 —The major arbitration systems—The American Arbitration Association
- § 16:9 Enforceability of Mandatory Class Arbitration Clauses
- § 16:10 Enforceability of Mandatory Individual Arbitration Clauses vs. Class Action Litigation
- § 16:11 International dispute resolution—The major arbitration systems—The International Chamber of Commerce
- § 16:12 — —The London Court of International Arbitration
- § 16:13 —A note on the UNCITRAL arbitration rules
- § 16:14 —*Ad hoc* arbitration
- § 16:15 Enforceability of arbitration clauses in international distribution agreements

## PART VIII. ADMINISTRATION AND ENFORCEMENT

### CHAPTER 17. ANTITRUST LENIENCY AND SENTENCING

- § 17:1 Introduction
- § 17:2 Leniency policies
- § 17:3 —Corporate leniency policy
- § 17:4 —Individual leniency policy
- § 17:5 Compliance at the Charging Phase
- § 17:6 Federal sentencing
- § 17:7 —Corporate fines
- § 17:8 — —Establish the base fine

- § 17:9 — —Determine the “multiplier” and the culpability score
- § 17:10 —Corporate probation
- § 17:11 —Individual fines
- § 17:12 — —Determine the base offense level
- § 17:13 — —Adjusting the offense level
- § 17:14 —Individual incarceration
- § 17:15 Conclusion

## **CHAPTER 18. DEPARTMENT OF JUSTICE ADMINISTRATION: BUSINESS REVIEW LETTERS**

- § 18:1 Introduction
- § 18:2 Form of request; information required
- § 18:3 —Expedited review of proposed joint ventures
- § 18:4 —Expedited review of proposed information exchanges
- § 18:5 Timing
- § 18:6 DOJ procedures

## **PART IX. COUNSELING ISSUES**

### **CHAPTER 19. BASICS OF ANTITRUST COMPLIANCE PROGRAMS**

- § 19:1 Introduction
- § 19:2 What are the risks?
- § 19:3 What should the compliance program include?
- § 19:4 Some ancillary considerations
- § 19:5 —The organizational sentencing guidelines
- § 19:6 —The Department of Justice leniency program
- § 19:7 —The attorney-client privilege
- § 19:8 —The importance of white collar crime issues
- § 19:9 —The broad scope of the government’s subpoena powers
- § 19:10 The antitrust compliance policy
- § 19:11 The antitrust compliance manual—Basic elements
- § 19:12 —What might the manual say about the hard-core antitrust risks?
- § 19:13 —What should the manual say about other antitrust risks?
- § 19:14 — —Resale price maintenance
- § 19:15 — —Refusals to do business—Boycotts
- § 19:16 — —Reciprocity
- § 19:17 — —Tying arrangements
- § 19:18 — —Exclusive dealing
- § 19:19 — —Price discrimination—The Robinson-Patman Act

## TABLE OF CONTENTS

§ 19:20	— —Trade associations
§ 19:21	—Other considerations
§ 19:22	— —Monopolization
§ 19:23	— —Unfair competition
§ 19:24	— —Mergers, acquisitions, joint ventures
§ 19:25	— —Intellectual property
§ 19:26	— —International
§ 19:27	—Nonsubstantive matters, records, government investigations, and certification
§ 19:28	—Other written materials
§ 19:29	Tools in addition to the written materials
§ 19:30	—Oral presentations
§ 19:31	—Tests or exercises
§ 19:32	—Movies/videos
§ 19:33	—Other techniques
§ 19:34	The antitrust audit
§ 19:35	Procedures for review
§ 19:36	The counseling portion of the program
§ 19:37	List of dos and don'ts of antitrust

## CHAPTER 20. ANTITRUST ASPECTS OF DOING BUSINESS ABROAD

§ 20:1	Introduction
§ 20:2	U.S. antitrust laws and guidelines dealing with international business—The “bedrock” statutes
§ 20:3	—Antitrust Enforcement Guidelines for International Operations
§ 20:4	—Webb-Pomerene Act
§ 20:5	—Export Trading Company Act (ETCA)
§ 20:6	—National Cooperative Research and Production Act
§ 20:7	—Foreign Trade Antitrust Improvements Act
§ 20:8	—Other legislation
§ 20:9	International agreements
§ 20:10	—Bilateral agreements
§ 20:11	—Mutual legal assistance treaties
§ 20:12	—International Antitrust Enforcement Assistance Act
§ 20:13	International enforcement issues
§ 20:14	—Comity
§ 20:15	—The Foreign Sovereign Immunity Act (FSIA)
§ 20:16	—Foreign sovereign compulsion
§ 20:17	—Acts of state
§ 20:18	—Petitioning of sovereigns
§ 20:19	—Mergers and acquisitions
§ 20:20	—Political question doctrine
§ 20:21	Conclusion

## PART X. MISCELLANEOUS

### CHAPTER 21. ANTITRUST AND EMPLOYMENT

- § 21:1 Introduction
- § 21:2 The labor organization exemption—Section 6 of the Clayton Act
- § 21:3 “No poach” agreements—DOJ & FTC Enforcement Actions and Guidelines
- § 21:4 Salary surveys
- § 21:5 —Salary surveys in the health care industry—Guidelines and business review letters
- § 21:6 — —Health care cases
- § 21:7 —Exchanges of salary information outside the health care industry
- § 21:8 — —Business review letters
- § 21:9 — —Cases involving the exchange of salary information
- § 21:10 Restrictive covenants in employment contracts
- § 21:11 Restrictive covenants—Covenants not to compete
- § 21:12 — —Analyzing restrictive covenants under federal antitrust law
- § 21:13 — —Sherman Act § 1—Restraints of trade—The rule of reason
- § 21:14 — — — —Product market versus labor market
- § 21:15 — —Sherman Act § 2—Monopolization
- § 21:16 — —Forfeiture cases
- § 21:17 — —“No hire” agreements
- § 21:18 — —Ancillary restraints
- § 21:19 — —“No hire” agreements—Clayton Act issues—Antitrust Injury and Standing under § 4 of the Clayton Act
- § 21:20 — —“No hire” agreements—Clayton Act issues—The Clayton Act labor exemption
- § 21:21 — —Substantive antitrust analysis
- § 21:22 — — — —Sherman Act cases
- § 21:23 — — — —The FTC Act
- § 21:24 Standing of terminated employees
- § 21:25 —Supreme Court guidance
- § 21:26 —The lower court split on the antitrust standing of terminated employees
- § 21:27 — —Cases that approve standing
- § 21:28 — —Cases that deny standing
- § 21:29 Conclusion

### CHAPTER 22. ANTITRUST AND E-COMMERCE

- § 22:1 Introduction

## TABLE OF CONTENTS

§ 22:2	Market power
§ 22:3	—The <i>Microsoft</i> case
§ 22:4	—Online marketplaces
§ 22:5	Standards setting
§ 22:6	Standard Setting—Standard Essential Patents (SEPs)
§ 22:7	Distribution/online retailing—Resale price maintenance
§ 22:8	—Horizontal boycotts
§ 22:9	—Robinson-Patman Act
§ 22:10	Intellectual property
§ 22:11	Recent Decisions
§ 22:12	Conclusion

## CHAPTER 23. TRADE ASSOCIATIONS

§ 23:1	Introduction
§ 23:2	Overview of the antitrust problem
§ 23:3	Informal discussions
§ 23:4	Membership restrictions
§ 23:5	Availability of benefits to nonmembers
§ 23:6	Programs involving certification or standards setting
§ 23:7	Restrictions on member conduct
§ 23:8	Joint political activity
§ 23:9	Information sharing programs
§ 23:10	Association and member liability for trade association activities
§ 23:11	Joint research and development
§ 23:12	Joint exporting activity
§ 23:13	Summary and conclusion

Appendix 23-A. Sample Compliance Program

### Table of Laws and Rules

### Table of Cases

### Index